The company had sales of RON409.7 million and a profit of RON7 million in 2012.
Ropharma’s operating profit increased 10%, to RON10.5 million, from RON9.6 million in 2012, according to its preliminary earnings report. The company’s debts decreased nearly 10% last year, to RON227.5 million from RON251.3 million in 2012.
According to the latest reports to the stock exchange, businessman Mihai Miron indirectly owns 32.24% of Ropharma. He controls 14.71% via Rimia Investments and 17.53% via ADD Pharmaceuticals. U.S.-registered Arrow Pharmaceuticals owns 31.29% in Ropharma.
Other shareholders include private pension funds AZT Viitorul Tau – Allianz, with 5.87%, and ING with 4.99%.
Ropharma shares ended down 1.47% Monday, at RON0.335 a share.